Clinical Trial with Universal Vaccine Increases Response Rate of Subjects Generating Infection-Preventing Antibodies by 100% in Population Most at Risk for Flu Deaths

No Vaccine or Cure Exists For Virus That Can Be Life Threatening to Infants, Immune Compromised, and Transplant Patients; Highly Pervasive Virus Also Implicated in Cancers, Inflammatory Diseases, and Cardiovascular Diseases

Biotech Broadens IP Encompassing Synthetic Vaccines Against Cancer, Infectious Disease and Biodefense Pathogens

Inovio Advances New Disease Therapy, Where 400 Million Patients Lack Effective Treatment

Plasmid Therapy Increases Live Births in Pigs; Previously Approved in Australia

-- Article in Peer-Reviewed Science-Translational Medicine Reports Strong and Durable T Cell Responses from VGX-3100, Which is Designed to Treat Cervical Dysplasias Caused by HPV Infection

New Preclinical Data Paves Way for Large Scale Vaccine Administration

Manuscript Published in American Journal of Veterinary Research Highlights One Treatment with LifeTide Results in More Live Pigs per Litter and Higher Birth and Weaning Weights

Flu Vaccine Shows Protective Immune Responses in Humans Against the Nine Key H1N1 Flu Strains of Past 100 Years, Including 1918 Pandemic Flu

Company invites individual and institutional investors to log-on to view presentation

Clinical Study of SynCon® Influenza Vaccine Alone and With Seasonal H1N1 Vaccine Will Measure Universal Antibody Responses and T-Cell Responses, Which May be Vital to Fighting Influenza in Elderly

Cabrera led Thunderbird School of Management and will soon take reins as president of George Mason University

Inovio Synthetic DNA Vaccine Achieves Proof of Principle With Robust Antibody and T Cell Responses Against Diverse H5N1 Influenza Strains